Agilon Health (AGL Quick QuoteAGL - Free Report) reported $1.42 billion in revenue for the quarter ended March 2026, representing a year-over-year decline of 7.3%. EPS of $1.80 for the same period compares to $0 a year ago.

The reported revenue represents a surprise of +3.28% over the Zacks Consensus Estimate of $1.38 billion. With the consensus EPS estimate being $1.13, the EPS surprise was +58.73%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Agilon performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Avg. Medicare Advantage Members: 424,000 versus 473,750 estimated by two analysts on average.
• Revenues- Medical services: $1.42 billion versus the three-analyst average estimate of $1.37 billion. The reported number represents a year-over-year change of -7.3%.
• Revenues- Other operating: $1.91 million compared to the $2.83 million average estimate based on three analysts. The reported number represents a change of -34.2% year over year.

View all Key Company Metrics for Agilon here>>>

Shares of Agilon have returned +61.2% over the past month versus the Zacks S&P 500 composite's +10.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.